Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

And this time, it’s not just fringe actors fanning the flames. It’s policymakers. It’s media personalities. It’s individuals ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.

The preservative thimerosal started Robert F. Kennedy Jr. down the path of questioning vaccine safety. A panel of experts he ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

Dr. Levi and Vicky Pebsworth, a nurse affiliated with an anti-vaccine group, voted against recommending clesrovimab; the ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...